<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2009, p. 525&#226;&#8364;&#8220;530                                                                  Vol. 53, No. 2 <br /> 0066-4804/09/$08.00&#226;&#171;&#185;0 doi:10.1128/AAC.00917-08 <br /> Copyright &#194;&#169; 2009, American Society Microbiology. All Rights Reserved. <br />  <br />  <br />  <br />                   Variations Amino Acid Composition Antisense <br />                   Peptide-Phosphorodiamidate Morpholino Oligomer <br />                     Affect Potency Escherichia coli In Vitro <br />                                      In Vivo&#228;&#338;&#164; <br />    Brett L. Mellbye,1 Susan E. Puckett,2 Luke D. Tilley,1 Patrick L. Iversen,1 Bruce L. Geller1,2* <br />                                 AVI BioPharma, Inc.,1 Oregon State University,2 Corvallis, Oregon <br />                       Received 10 July 2008/Returned modification 24 September 2008/Accepted 7 November 2008 <br />  <br />              The potency antisense peptide-phosphorodiamidate morpholino oligomers (PPMOs) improved by <br />           varying peptide composition. An antisense phosphorodiamidate morpholino oligomer (PMO) complemen- <br />           tary mRNA essential gene acpP (which encodes acyl carrier protein required lipid <br />           biosynthesis) Escherichia coli conjugated 5&#226;&#180;&#8226; ends various cationic membrane-penetrating <br />           peptides. Each peptide repeating sequence motifs: C-N-N (motif 1), C-N (motif 2), C-N-C <br />           (motif 3), C cationic residue N nonpolar residue. Variations cationic residues included <br />           arginine, lysine, ornithine (O). Variations nonpolar residues included phenylalanine, valine, <br />           &#226;?&#164;-alanine (B), 6-aminohexanoic acid (X). The MICs PPMOs varied 0.625 &gt;80 &#226;?&#174;M (about <br />           3 480 &#226;?&#174;g/ml). Three potent (RX)6B-, (RXR)4XB-, (RFR)4XB-AcpP PMOs, which <br />           tested mice infected E. coli. The (RXR)4XB-AcpP PMO potent three <br />           conjugates tested mice. The administration 30 &#226;?&#174;g (1.5 mg/kg body weight) (RXR)4XB-AcpP PMO at <br />           15 min postinfection reduced CFU/ml blood 102 103 2 12 h compared numbers in <br />           water-treated controls. All mice treated 30 &#226;?&#174;g/dose (RXR)4XB-AcpP PMO survived infection, whereas <br />           water-treated mice died 12 h postinfection. The reduction CFU/ml blood proportional dose <br />           PPMO 30 300 &#226;?&#174;g/ml. In summary, C-N-C motif effective motifs, <br />           arginine effective lysine ornithine, phenylalanine effective 6-aminohexanoic <br />           acid vitro necessarily vivo, (RXR)4XB-AcpP PMO reduced bacterial infection promoted <br />           <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-40' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-48' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-50' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-52' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-53' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-66' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-67' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-70' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-77' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-80' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span>survival</span> clinically relevant doses. <br />  <br />  <br />   Antibiotic resistance bacteria, increasing incidence,              conjugated counterparts (7, 10). Apparently, membrane- <br /> and decreasing rate discovery new antibiotics create            penetrating peptide carries cargo (the antisense <br /> need new strategies targeting bacterial components               oligomer) outer membrane gram-negative bac- <br /> antibiotic therapy. Genomics created attractive oppor-               teria, traverses plasma membrane an <br /> tunity target specific genes inhibition use                unknown mechanism. <br /> antisense oligomers silence essential genes.                                Membrane-penetrating peptides diverse sequences, <br />   Synthetic antisense oligomers DNA mimics bind                    cationic amphipathic. Previous investiga- <br /> <span id='am-3' about='protege:TO' typeof='owl:Thing'>to</span> target RNA complementary <span id='am-82' about='xsp:base' typeof='owl:Thing'>base</span> pairing. When                      tions suggest repeated peptide motif cationic <br /> antisense oligomers added pure bacterial cultures,                   residue followed nonpolar residues may <br /> they shown decrease levels expression                important feature efficient membrane penetration <br /> reporter genes luciferase (5, 7), activate endogenous               (25). <br /> genes &#226;?&#164;-galactosidase (7), inhibit growth tar-                   Antisense oligomers conjugated peptides (KFF)3 <br /> geting essential genes RNA (9, 10, 11, 14, 23, 28). In                   (RFF)3 targeted essential gene products potent <br /> addition, antisense oligomers reduce infection increase <br />                                                                             growth inhibitors E. coli, Salmonella enterica serovar Typhi- <br /> the survival mice infected Escherichia coli (8, 21, <br />                                                                             murium, Staphylococcus aureus, Mycobacterium smegmatis, and <br /> 22). <br />                                                                             Klebsiella pneumoniae (10, 13, 14, 23). Although antisense pep- <br />   Antisense oligomers require assistance gain entry into <br />                                                                             tide-oligomers variations peptide sequences have <br /> bacterial cells molecular weight polar <br />                                                                             screened efficacies gram-positive bacte- <br /> characteristics. Recently, antisense oligomers been <br />                                                                             rium S. aureus (17), effects variations the <br /> conjugated membrane-penetrating peptides. Peptide-oli- <br /> gomer conjugates significantly effective inhibit-               gram-negative bacterium E. coli reported (10, 23). <br /> ing expression specific targets non-                Moreover, reports effects of <br />                                                                             variations peptide sequences antisense peptide- <br />                                                                             oligomers animal models bacterial infection. <br />   * Corresponding author. Mailing address: Department Microbi-              In study described report, E. coli used to <br /> ology, 220 Nash Hall, Oregon State University, Corvallis, OR 97331- <br />                                                                             compare efficacies vitro vivo antisense pep- <br /> 3804. Phone: (541) 737-1845. Fax: (541) 737-0496. E-mail: gellerb <br /> @orst.edu.                                                                  tide-phosphorodiamidate morpholino oligomers (PPMOs) <br />   &#228;&#338;&#164; <br />     Published ahead print 17 November 2008.                           vary amino acid sequences. <br />  <br />                                                                       525 <br />  526       MELLBYE ET AL.                                                                                                         ANTIMICROB. AGENTS CHEMOTHER. <br />  <br />                         MATERIALS AND METHODS                                              TABLE 1. MICs peptide-AcpP11 PMO conjugates pure <br />    Bacterial strains. Wild-type strain E. coli K-12 W3110 used exper-                             cultures E. coli <br /> iments. Liquid cultures grown Mueller-Hinton II broth (for MIC                                                                                 MIC <br /> assays) LB broth (for preparation inoculum mice).                       Motif PMO no.                  Conjugated peptide <br />    MICs. MICs determined microdilution method (4). To control                                                                           &#226;?&#174;M          &#226;?&#174;g/ml <br /> nonspecific toxicity, peptide conjugated second phosphoro- <br /> diamidate morpholino oligomer (PMO) base sequence                Motif 1 (C-N-N) <br /> complementary gene E. coli. In cases, MIC control PPMO       05-0198                      RFFXB                              &#226;&#172;&#381;80       &#226;&#172;&#381;360 <br /> was limit measurement, 80 &#226;?&#174;M.                                  05-0197                      RFFRFFXB                            20         99 <br />    PMO. PPMOs synthesized AVI BioPharma (Corvallis, OR) de-                05-0200                      RFFRFFRFFRXB                         2.5       14 <br /> scribed previously (23). The base sequence AcpP PMO 5&#226;&#172;&#732;-CTTCGAT              05-0653                      DRFDFDRDFDFDRDFDFD                   5         28 <br /> AGTG-3&#226;&#172;&#732;, complementary bases 1153197 1153207 E. coli                                           RXBa <br /> W3110 genomic map (NCBI accession number AP009048). The target sequence                23-248                      RXXRXXRXXB                          20        102 <br /> is immediately 3&#226;&#172;&#732; start codon. The rationale <span id='am-2' about='xsp:length' typeof='owl:Thing'>length</span> position     06-0199                     KFFKFFKFFKXB                        10         54 <br /> the PMO target mRNA characterized previously (5). This PMO             06-0064                     RBBRBBRBBRXB                       &#226;&#172;&#381;80       &#226;&#172;&#381;408 <br /> sequence shown inhibit growth E. coli pure cultures (5, 8,       06-0079                     RVVRVVRVVRXB                       &#226;&#172;&#381;80       &#226;&#172;&#381;422 <br /> 23), infected tissue culture (23), mouse models infection (8, 22). The base     06-0082                     OFFOFFOFFOXB                       &#226;&#172;&#381;80       &#226;&#172;&#381;431 <br /> sequence nonsensical control PMOs 5&#226;&#172;&#732;-TCTCAGATGGT-3&#226;&#172;&#732;. The non- <br /> sensical (scrambled) sequence random sequence 11 bases used         Motif 2 (C-N) <br /> in AcpP PMO previously shown inhibit growth E.         06-0067                      RXRXB                              &#226;&#172;&#381;80       &#226;&#172;&#381;358 <br /> coli (5, 8, 23, 24).                                                                  06-0070                      RXRXRXRXB                           80        401 <br />    Mouse experiments. All mice infected treated PPMOs            06-0073                      RXRXRXRXRXRXB                        1.25       6.9 <br /> described previously (22). Briefly, groups mice infected     06-0761                      KXKXKXKXKXKXB                      &#226;&#172;&#381;80       &#226;&#172;&#381;430 <br /> the intraperitoneal injection E. coli W3110. The mice treated intra-       06-0762                      OXOXOXOXOXOXB                      &#226;&#172;&#381;80       &#226;&#172;&#381;424 <br /> peritoneal injection 15 min 12 h postinfection. Blood collected 2, <br /> 6, 12, 24, 48 h postinfection; diluted; plated determine numbers      Motif 3 (C-N-C) <br /> of viable bacteria.                                                                   06-0076                      RXRRXRRXRRXRXB                       1.25          7.2 <br />    All animal procedures approved Oregon State University Animal          06-0824                      KXKKXKKXKKXKXB                      20           111 <br /> Care Use Committee complied state federal laws.                  06-0763                      OXOOXOOXOOXOXB                      10            54 <br />    Statistical analysis. The mean numbers CFU/ml blood standard devi-          07-0795                      RFRRFRRFRRFRXB                       0.625         3.7 <br /> ation calculated treatment group using Prism (version 4.0)           07-1119                      RXRRBRRXRRBRXB                       2.5          14 <br /> software (GraphPad Software, San Diego, CA). Survival curves analyzed by <br /> the Kaplan-Meier method Prism (version 4.0) software. Group means          Control (ampicillin)                                               6.7            2.5 <br /> compared transforming numbers CFU/ml log CFU/ml using            a <br />                                                                                            D,   residue follows D-isomeric form. <br /> one-way analysis variance, parametric methods, Kolmogorov Smirnov <br /> normality test, Tukey-Kramer multiple comparison post test (InStat, <br /> version 3.05, software; GraphPad Software). <br />  <br />  <br />                                                                                      form (RFF)3RXB (PPMO 05-0653) MIC was <br />                                   RESULTS                                            times higher equivalent L-isomeric <br />    Efficacies various PPMOs pure culture. Various                              form (PPMO 05-0200). <br /> PPMOs synthesized base sequence targeting                            The MIC PPMO motif 2 (C-N) motif 3 <br /> a region near start codon mRNA acpP,                          (C-N-C) measured. PPMOs (RX)6B, (RXR)4XB, or <br /> different peptides attached 5&#226;&#172;&#732; end (Table 1). Each pep-                       (RFR)4XB potent PPMOs (RXX)3B or <br /> tide designed repeated sequence motifs:                        (RFF)3RXB. The substitution lysine ornithine for <br /> (i) C-N-N (motif 1), (ii) C-N (motif 2), (iii) C-N-C (motif 3),                   arginine PPMOs motif 2 3 reduced potency. Two <br /> where C cationic residue N nonpolar residue. The                       tandem copies RX potent tandem <br /> cationic amino acids used arginine, lysine,                       copies RX. <br /> ornithine (O); nonpolar amino acids used                              Mouse peritonitis. The (RX)6B-AcpP PMO, (RXR)4XB- <br /> were phenylalanine, valine, &#226;?&#164;-alanine (B), 6-aminohex-                           AcpP PMO, (RFR)4XB-AcpP PMO tested mice <br /> anoic acid (X).                                                                      infected E. coli. Groups mice treated various <br />    The MIC PPMO motif 1 (C-N-N) mea-                                doses PPMOs ranging 10 300 &#226;?&#174;g 15 min 12 h <br /> sured shown Table 1. Control PPMOs                           postinfection. <br /> peptides attached PMO complementary se-                                  The results (RXR)4XB-AcpP PMO the <br /> quence MICs 80 &#226;?&#174;M (data shown). The results                            potent PPMOs tested mice (compare <br /> indicate potent PPMO peptide motif 1                          effects 30-&#226;?&#174;g dose PPMO shown Fig. 1A, <br /> (RFF)3RXB, 2.5 times potent                                B, E, F, G, H). One 30-&#226;?&#174;g dose (1.5 mg/kg body weight) <br /> ampicillin molar basis. Furthermore, increasing num-                        (RXR)4XB-AcpP PMO significantly (P &#226;&#172;? 0.001) re- <br /> ber RFF repeat units reduced MIC                            duced levels bacteria blood 98% 2 h <br /> &#226;&#172;&#381;32-fold &#226;&#172;&#381;80 2.5 &#226;?&#174;M. The replacement arginine                             compared levels water- scrambled-sequence- <br /> with lysine ornithine increased MIC 4-fold                             PPMO-treated controls. Higher doses (100 &#226;?&#174;g 300 &#226;?&#174;g) of <br /> &#226;&#172;&#381;32-fold, respectively. The substitution valine, &#226;?&#164;-alanine,                       (RXR)4XB-AcpP PMO reduced CFU/ml the <br /> or 6-aminohexanoic acid phenylalanine increased                              blood proportionally 2.5 4 orders magnitude <br /> MICs eightfold (compare MICs PPMOs 06-                               12 h posttreatment. All mice treated the <br /> 0079, 06-0064, 23-248 MIC PPMO 05-0200                               30-&#226;?&#174;g, 100-&#226;?&#174;g, 300-&#226;?&#174;g dose survived infection. There <br /> in Table 1). Interestingly, PPMO D-isomeric                             significant difference (P &#226;&#172;&#381; 0.05) rates survival <br />  VOL. 53, 2009                                                                         ANTISENSE MORPHOLINO POTENCY                 527 <br />  <br />  <br />  <br />  <br />   FIG. 1. Bacteria blood survival mice. Groups mice (n &#226;&#171;&#189; 3 7) infected E. coli treated 15 min 12 h <br /> postinfection (arrows) various PPMOs, scrambled-base-sequence (Scr) (RXR)4XB PPMO, ampicillin. Blood collected the <br /> indicated times spread LB plates determine numbers CFU. (A B) (RXR)4XB-PMO; (C D) ampicillin; (E F) <br /> (RX)6B-PMO; (G H) (RFR)4XB-PMO. Error bars indicate standard deviations. <br />  <br />  <br />  <br /> between group treated water treated 10        B). The 30-&#226;?&#174;g dose (RX)6B-AcpP PMO signifi- <br /> &#226;?&#174;g.                                                                  cantly (P &#226;&#172;? 0.001) reduced CFU/ml blood 88% 2 h <br />    Groups mice treated 30-&#226;?&#174;g, 100-&#226;?&#174;g, 300-&#226;?&#174;g       postinfection. The 100-&#226;?&#174;g 300-&#226;?&#174;g doses significantly <br /> dose ampicillin comparison results ob-        (P &#226;&#172;? 0.001) reduced CFU/ml blood equally 3 <br /> tained mice treated PPMO (Fig. 1C D). Thirty-         orders magnitude times postinfection. All mice treated <br /> microgram doses ampicillin ineffective reducing           100 &#226;?&#174;g/dose (RX)6B-AcpP PMO survived, sig- <br /> CFU/ml blood increasing rate survival. Both      nificant numbers mice did survive treatment 10 &#226;?&#174;g, <br /> the higher doses ampicillin significantly (P &#226;&#172;? 0.001) reduced     30 &#226;?&#174;g, 300 &#226;?&#174;g dose. <br /> CFU/ml blood 3 3.5 orders magnitude           The (RFR)4XB-AcpP PMO significantly reduced the <br /> increased rate survival 100% 48 h.                   numbers bacteria blood promoted survival (Fig. <br />    The (RX)6B-AcpP PMO significantly reduced CFU/ml               1G H). Doses 10 &#226;?&#174;g 30 &#226;?&#174;g did significantly (P &#226;&#172;&#381; <br /> blood (Fig. 1E F), potent          0.05) reduce CFU/ml blood time. Doses 100 &#226;?&#174;g <br /> (RXR)4XB-AcpP PMO (compare Fig. 1E F Fig. 1A                300 &#226;?&#174;g significantly (P &#226;&#172;? 0.01 &#226;&#172;? 0.001, respectively) <br />  528     MELLBYE ET AL.                                                                               ANTIMICROB. AGENTS CHEMOTHER. <br />  <br />  <br /> reduced CFU/ml blood 2 h posttreatment. The            PPMOs amino acid sequence repeat similar of <br /> CFU/ml blood reduced proportionally dose,          (RFF)3RXB-AcpP (repeat motif 1; Table 1), arginine supe- <br /> the 300-&#226;?&#174;g dose showed reduction (2 3 orders          rior lysine ornithine phenylalanine superior to <br /> magnitude) 2, 6, 12 h postinfection. The number            valine, &#226;?&#164;-alanine, 6-aminohexanoic acid. Among PPMOs <br /> surviving mice proportional dose.                         repeat motifs 2 3, trends similar for <br />                                                                      motif 1, valine &#226;?&#164;-alanine evaluated as <br />                          DISCUSSION                                  substitutes nonpolar residues. Unfortunately, attempts to <br />                                                                      synthesize (RF)6XB-AcpP PMO unsuccessful be- <br />    The purpose experiments increase po-            cause insoluble aqueous solution. These effects have <br /> tency antisense PPMOs targeted essential gene              observed antimicrobial peptides (18, 26). Because <br /> acpP, previously shown inhibit growth E.         role cationic chains make initial electrostatic <br /> coli pure culture infected mice (22). We              contact anionic moieties lipids (3, 29), results <br /> hypothesized efficacies PPMOs increase          consistent suggestion dispersed <br /> varying order cationic nonpolar amino acid res-           positive charge guanidinium group arginine elec- <br /> idues repeating motif replacing arginine            trostatically interact anionic moieties lipids a <br /> with cationic amino acids, phenylalanine            productive manner lysine ornithine (18, <br /> nonpolar amino acids, naturally occurring amino acids             26). The superior effect phenylalanine thought be <br /> with nonprotein amino acids. The rationale including             attributable bulkiness (19, 20). <br /> nonprotein amino acids peptide moiety pro-              Another interesting result D-isomers place of <br /> teolytic degradation reduced.                               L-isomers arginine phenylalanine increased MIC by <br />    Previously, Vaara Porro (25) suggested possibility        factor 2. This suggests mechanism entry of <br /> that repeating amino acid sequence motifs (cationic-hydro-       PPMOs outer membrane E. coli receptor <br /> phobic-hydrophobic) (cationic-hydrophobic) influ-          mediated. Our result consistent previous results and <br /> ence membrane-penetrating characteristics peptides.           models predicted cationic amphipathic <br /> Their results suggest motif effective        peptides penetrate directly membrane lipids (6, 16, <br /> than motif disorganizing outer membrane         29, 30). <br /> gram-negative bacteria. Although experiments used com-            The (RX)6B-, (RXR)4XB-, (RFR)4XB-AcpP PMOs <br /> pletely different end point used experiments     significantly reduced infections mice. The <br /> Vaara Porro (25), results spacing           (RXR)4XB-AcpP PMO reduced levels bacteremia a <br /> cationic nonpolar residues does effect support       dose-dependent manner, (RX)6B-AcpP PMO re- <br /> the suggestion motif cationic-nonpolar-cationic        duced CFU/ml blood similar extents 100 &#226;?&#174;g and <br /> residues slightly effective motifs        300 &#226;?&#174;g dose. The response treatment the <br /> tested.                                                              (RFR)4XB-AcpP PMO proportional dose early <br />    The mechanisms amphipathic peptides penetrate            times treatment, reflected rate of <br /> biological membranes controversial depend             survival. The (RXR)4XB-AcpP PMO potent of <br /> structures compositions peptides target               PPMOs tested, 100% mice survived treat- <br /> membranes (12, 29). Although experiments di-              ment dose low 30 &#226;?&#174;g (1.5 mg/kg). <br /> rectly address mechanism penetration, results            The (RXR)4XB-AcpP PMO potent ampi- <br /> consistent presented reports demon-         cillin. In vitro MIC analysis showed molar basis, <br /> strate importance number repeating sequence            PPMO times potent. Because the <br /> motifs choice cationic nonpolar amino acids. In       molecular weight (RXR)4XB-AcpP PMO 16 <br /> a recent study, number RW sequence repeats varied         times greater ampicillin, basis weight, <br /> <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> (15). The optimal number            (RXR)4XB-AcpP PMO times potent <br /> three. Our results RFF repeats        vitro. However, mouse model infection used for <br /> ineffective RFF repeats significantly in-         experiments, (RXR)4XB-AcpP PMO po- <br /> creased efficacy. However, RX repeats inef-         tent, weight basis. Clearly, 30 &#226;?&#174;g the <br /> fective, RX repeats highly effective. A similar         (RXR)4XB-AcpP PMO effective lowering <br /> effect shown uptake PPMOs HeLa              CFU/ml blood promoting survival 30 &#226;?&#174;g of <br /> cells (27). This suggests length overall   ampicillin (compare Fig. 1A B Fig. 1C D). We <br /> charge peptide important number         conclude (RXR)4XB-AcpP PMO potent <br /> of repeats. Alternatively, effect influenced       ampicillin reducing CFU/ml blood increasing <br /> bulkiness hydrophobicity nonpolar chains. Be-         rate survival, model infection that <br /> cause 6-aminohexanoic acid chain, presumed           used testing. <br /> interaction hydrophobic core bilayer             Although (RFR)4XB-AcpP PMO lowest MIC, it <br /> quite different phenylalanine. Previous results         effective PPMO vivo. The reason this <br /> have concluded short membrane-penetrating peptides          unclear, possibility composition re- <br /> (such ones used), composition amino        peat <span id='am-83' about='xsp:pattern' typeof='owl:Thing'>pattern</span> natural amino acids suscep- <br /> acids important order amino acids            tible proteolysis animals. Alternatively, less <br /> (19, 20).                                                            favorable pharmacokinetics bioavailability other <br />    The results vitro testing showed             PPMOs. <br />  VOL. 53, 2009                                                                                         ANTISENSE MORPHOLINO POTENCY                              529 <br />  <br />  <br />    Thirty percent mice treated 300 &#226;?&#174;g/dose (RX)6B-                     3. Brown, K. L., R. E. W. Hancock. 2006. Cationic host defense (antimi- <br />                                                                                       crobial) peptides. Curr. Opin. Immunol. 18:24&#226;&#8364;&#8220;30. <br /> AcpP PMO died, despite having levels bacteria blood                      4. Clinical Laboratory Standards Institute. 2006. Methods dilution <br /> comparable blood mice treated 100                             antimicrobial susceptibility tests bacteria grow aerobically, 7th ed., <br /> &#226;?&#174;g/dose, survived. These results suggest                        approved standard M7-A7. Clinical Laboratory Standards Institute, <br />                                                                                       Wayne, PA. <br /> (RX)6B-AcpP PMO toxic mice 300-&#226;?&#174;g/dose                            5. Deere, J., P. Iversen, B. L. Geller. 2005. Antisense phosphorodiami- <br /> (&#226;&#172;&#402;15 mg/kg), account lack ability                          date morpholino oligomer length target position effects gene- <br /> further reduce CFU/ml blood compared numbers                            specific inhibition Escherichia coli. Antimicrob. Agents Chemother. <br />                                                                                       49:249&#226;&#8364;&#8220;255. <br /> in group treated 100 &#226;?&#174;g/dose. Similar PPMOs                      6. Dennison, S. R., J. Wallace, F. Harris, D. A. Phoenix. 2005. Amphiphilic <br /> RX repeating motif toxic tissue culture (27). The                         &#226;?&#163;-helical antimicrobial peptides structure/function relationships. <br />                                                                                       Protein Pept. Lett. 12:31&#226;&#8364;&#8220;39. <br /> apparent toxicity mice likely caused peptide moiety                   7. Geller, B. L., J. D. Deere, D. A. Stein, D. Kroeker, H. M. Moulton, P. L. <br /> or conjugate, PMO attached pep-                            Iversen. 2003. Inhibition gene expression Escherichia coli antisense <br /> tide nontoxic doses (8).                                                  phosphorodiamidate morpholino oligomers. Antimicrob. Agents Che- <br />                                                                                       mother. 47:3233&#226;&#8364;&#8220;3239. <br />    If (RX)6B-AcpP PMO toxic 15 mg/kg, rela-                         8. Geller, B. L., J. Deere, L. Tilley, P. L. Iversen. 2005. Antisense phos- <br /> tively short time death (12 h) bit unusual suggests                     phorodiamidate morpholino oligomer inhibits viability Escherichia coli in <br /> rapid event lipopolysaccharide-induced cytokine cas-                        pure culture mouse peritonitis. J. Antimicrob. Chemother. 55:983&#226;&#8364;&#8220; <br />                                                                                       988. <br /> cade. Alternatively, plausible arginines (RX)6                   9. Good, L., P. E. Nielsen. 1998. Inhibition translation bacterial <br /> could converted NO nitric oxide synthase. This                         growth peptide nucleic acid targeted ribosomal RNA. Proc. Natl. Acad. <br />                                                                                       Sci. USA 95:2073&#226;&#8364;&#8220;2076. <br /> lead critical events lung, heart, brain, which <br />                                                                                   10. Good, L., S. K. Awasthi, R. Dryselius, O. Larsson, P. E. Nielsen. 2001. <br /> could lead death 12 h.                                                          Bacterial antisense effects peptide-PNA conjugates. Nat. Biotechnol. 19: <br />    There apparent short-term, gross toxicity                          360&#226;&#8364;&#8220;364. <br />                                                                                   11. Gruegelsiepe, H., O. Brandt, R. K. Hartmann. 2006. Antisense inhibi- <br /> (RXR)4XB-AcpP PMO, highest dose tested (300                               tion RNase P: mechanistic aspects application live bacteria. J. Biol. <br /> &#226;?&#174;g [15 mg/kg]), determined 100% survival rate                            Chem. 281:30613&#226;&#8364;&#8220;30620. <br /> mice treatment group. Previous results shown                    12. Henriques, S. T., M. N. Melo, M. A. R. B. Castanho. 2006. Cell-pene- <br />                                                                                       trating peptides antimicrobial peptides: different they? Bio- <br /> a (RXR)4XB PMO causes significant toxicity 150 mg/kg                            chem. J. 399:1&#226;&#8364;&#8220;7. <br /> rats 50% lethal dose 210 mg/kg (2). If                   13. Kulyte, A., N. Nekhotiaeva, S. K. Awasthi, L. Good. 2005. Inhibition of <br /> safety values converted mice use                           Mycobacterium smegmatis gene expression growth using antisense pep- <br />                                                                                       tide nucleic acids. J. Mol. Microbiol. Biotechnol. 9:101&#226;&#8364;&#8220;109. <br /> conventional surface area calculations (24), toxicity mice                 14. Kurupati, P., K. S. W. Tan, G. Kumarasinghe, C. L. Poh. 2007. Inhibi- <br /> would translate 300 mg/kg. Thus, estimated ther-                         tion gene expression growth antisense peptide nucleic acids a <br />                                                                                       multiresistant &#226;?&#164;-lactamase-producing Klebsiella pneumonia strain. Antimi- <br /> apeutic index (50% lethal dose/50% effective dose)                             crob. Agents Chemother. 51:805&#226;&#8364;&#8220;811. <br /> (RXR)4XB-AcpP PMO greater 200 (300 mg/kg/                             15. Liu, Z., A. Brady, A. Young, B. Rasimick, K. Chen, C. Zhou, N. R. <br /> 1.5 mg/kg).                                                                           Kallenbach. 2007. Length effects antimicrobial peptides (RW)n <br />                                                                                       series. Antimicrob. Agents Chemother. 51:597&#226;&#8364;&#8220;603. <br />    Recently, (RXR)4 efficiently deliver                         16. Maloy, W. L., U. P. Kari. 1995. Structure-activity studies magainins <br /> PMOs eukaryotic cell plasma membrane                                 host defense peptides. Biopolymers 37:105&#226;&#8364;&#8220;122. <br /> HeLa CHO cells (1). Although mechanism entry                            17. Nekhotiaeva, N., S. K. Awasthi, P. E. Nielsen, L. Good. 2004. Inhibition <br />                                                                                       Staphylococcus aureus gene expression growth using antisense peptide <br /> across eukaryotic cell plasma membrane apparently                              nucleic acids. Mol. Ther. 10:252&#226;&#8364;&#8220;259. <br /> mediated binding proteoglycan, mechanism sub-                        18. Shafer, W. M., F. Hubalek, M. Huang, J. Pohl. 1996. Bactericidal <br />                                                                                       activity synthetic peptide (CG 117-136) human lysosomal cathep- <br /> sequent transit internal membranes nu-                            sin G dependent arginine content. Infect. Immun. 64:4842&#226;&#8364;&#8220;4845. <br /> cleus unknown. The ability (RXR)4XB mediate                          19. Strom, M. B., B. E. Haug, O. Rekdal, M. L. Skar, W. Stensen, J. S. <br /> entry PMOs eukaryotic prokaryotic cells                              Svendsen. 2003. Important structural features 15-residue lactoferricin <br />                                                                                       derivatives methods improvement antimicrobial activity. Biochem. <br /> suggests antibacterial PPMOs designed use                           Cell Biol. 80:65&#226;&#8364;&#8220;74. <br /> against intracellular bacteria. Indeed, preliminary data in-                      20. Strom, M. B., O. Rekdal, J. S. Svendsen. 2002. Antimicrobial activity of <br /> dicate (RXR)4XB PMOs targeted specific essential                              short arginine- tryptophan-rich peptides. J. Pept. Sci. 8:431&#226;&#8364;&#8220;437. <br />                                                                                   21. Tan, X.-X., J. K. Actor, Y. Chen. 2005. Peptide nucleic acid antisense <br /> genes significantly reduce intracellular Salmonella, Chlamydia,                       oligomer therapeutic strategy bacterial infection: proof prin- <br /> and Mycobacterium levels (G. Mitev B. L. Geller, unpub-                           ciple using mouse intraperitoneal infection. Antimicrob. Agents Chemother. <br /> lished data).                                                                         49:3203&#226;&#8364;&#8220;3207. <br />                                                                                   22. Tilley, L. D., B. L. Mellbye, S. E. Puckett, P. L. Iversen, B. L. Geller. <br />                                                                                       2007. Antisense peptide-phosphorodiamidate morpholino oligomer conju- <br />                         ACKNOWLEDGMENTS                                               gate: dose-response mice infected Escherichia coli. J. Antimicrob. <br />                                                                                       Chemother. 59:66&#226;&#8364;&#8220;73. <br />   We thank entire chemistry department AVI BioPharma                   23. Tilley, L. D., O. S. Hine, J. A. Kellogg, J. N. Hassinger, D. D. Weller, P. L. <br /> making purifying PPMOs. We thank Alix Gitelman advice                     Iversen, B. L. Geller. 2006. Gene-specific effects antisense phos- <br /> on statistical analysis.                                                              phorodiamidate morpholino oligomer-peptide conjugates Escherichia <br />   This work funded AVI BioPharma.                                              coli Salmonella enterica serovar Typhimurium pure culture in <br />   Bruce Geller employed AVI BioPharma Oregon                          tissue culture. Antimicrob. Agents Chemother. 50:2789&#226;&#8364;&#8220;2796. <br />                                                                                   24. U.S. Food Drug Administration, Center Drug Evaluation Re- <br /> State University.                                                                     search. 2008. Dose calculator convert animal dose human equivalent <br />                                                                                       dose. Center Drug Evaluation Research, U.S. Food Drug Ad- <br />                                REFERENCES                                             ministration, Rockville MD. http://www.fda.gov/cder/cancer/animalframe <br /> 1. Abes, S., H. M. Moulton, P. Clair, P. Prevot, D. S. Youngblood, R. P. Wu,          .htm. Date accessed, 7 July 2008. <br />    P. L. Iversen, B. Lebleu. 2006. Vectorization morpholino oli-           25. Vaara, M., M. Porro. 1996. Group peptides act synergistically <br />    gomers (R-Ahx-R)4 peptide allows efficient splicing correction           hydrophobic antibiotics gram-negative enteric bacteria. Antimi- <br />    absence endosomolytic agents. J. Control. Release 116:304&#226;&#8364;&#8220;313.              crob. Agents Chemother. 40:1801&#226;&#8364;&#8220;1805. <br /> 2. Amantana, A., H. M. Moulton, M. L. Cate M.  <br /> </body></html>